- Home
- ARWR
as of 12-11-2025 3:43pm EST
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | PASADENA |
| Market Cap: | 5.6B | IPO Year: | 1993 |
| Target Price: | $60.70 | AVG Volume (30 days): | 3.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.57 - $72.36 | Next Earning Date: | 11-25-2025 |
| Revenue: | $829,448,000 | Revenue Growth: | 23258.15% |
| Revenue Growth (this year): | -52.06% | Revenue Growth (next year): | -26.54% |
AI-Powered ARWR Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Arrowhead Pharmaceuticals Inc. (ARWR)
Director
Avg Cost/Share
$61.03
Shares
16,250
Total Value
$991,737.50
Owned After
115,240
SEC Form 4
Director
Avg Cost/Share
$56.39
Shares
8,750
Total Value
$493,412.50
Owned After
68,764
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$35.00
Shares
20,000
Total Value
$700,000.00
Owned After
212,122
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| PERRY MICHAEL S | ARWR | Director | Dec 5, 2025 | Sell | $61.03 | 16,250 | $991,737.50 | 115,240 | |
| Ferrari Mauro | ARWR | Director | Nov 28, 2025 | Sell | $56.39 | 8,750 | $493,412.50 | 68,764 | |
| Hamilton James C | ARWR | Chief Medical Officer | Oct 1, 2025 | Sell | $35.00 | 20,000 | $700,000.00 | 212,122 |
Compare ARWR vs Leading Stocks
See how ARWR stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ARWR Arrowhead Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.